Early detection of cancer.
Early detection of cancer.
IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
South Korean liquid biopsy firm IMBdx said Thursday that it is expanding an ongoing collaboration with AstraZeneca under a project called PROSPER 2.0, which aims to improve access to targeted therapies for individuals with metastatic prostate cancer in markets outside the US. Financial terms of the partnership were not disclosed. IMBdx offers a blood-based next-generation sequencing test called AlphaLiquid HRR, which analyzes circulating tumor DNA in plasma to detect alterations in 15 genes associated with homologous recombination repair. The assay is currently available in various countries including Ukraine, Australia, Taiwan, Malaysia, Vietnam, Colombia, Mexico, Lebanon, United Arab Emirates, Saudi Arabia, and Kuwait, the company said. As part of the PROSPER 2.0 project, IMBdx and AstraZeneca are exploring ways to increase clinician and patient awareness of the availability and utility of ctDNA testing to guide the use of targeted therapies in advanced prostate cancer, and of the capabilities of the AlphaLiquid HRR ctDNA test in particular. IMBdx said it has been developing the test for more than two years, including in a collaborative study with Seoul National University Hospital that provided HRR results for 92 percent of patients using blood samples and demonstrated high concordance with tissue biopsy results. GenomeWeb, 2023
IMBDx Attends 'KoreaBIO X BioCentury X Sidley Austin 2021 Global IR' for Domestic Bio Startups
On January 21st, 2021 IMB Dx attended the 'KoreaBIO X BioCentury X Sidley Austin 2021 Global IR,' held for the purpose of supporting Korean biotech startups with global network building and overseas expansion. As an additional event to the JP Morgan Healthcare Conference, this online event was sponsored by the Korea Biotechnology Industry Organization (Korea BIO), BioCentury, and Sidley Austin LLP. At the event, IMB Dx CEO Peter Moon pitched the company's outstanding potential and technologies for global expansion and investment attraction. Watch CEO Moon pitching at the Global IR event below, followed by a short video of him introducing AlphaLiquid®100, filmed with the support of Invest Korea.
IMBDx to Attend Bio Health Worldwide Online 2020
IMB Dx is attending the ‘Bio Health Worldwide Online 2020’ exhibit sponsored by KOTRA and the South Korean Ministry of Trade, Industry and Energy which will be held for 12 days beginning October 19th, 2020. Over 500 companies in the fields of biotechnology, pharmaceutical, medical device, healthcare, dietary supplements, and protective supplies, as well as over 1,000 potential buyers fr|om all over the world, are expected to attend. The exhibit will be held entirely virtually due to COVID-19. At its virtual exhibition booth, IMB Dx will be presenting its liquid biopsy platform, the AlphaLiquid® product series, which detects and monitors minuscule amount of tumor DNA in the blood with high sensitivity. IMB Dx has already confirmed several meetings with various companies, including those fr|om China, Vietnam, and Germany, that have expressed interest in IMB Dx’s services. IMB Dx official said that the company plans on “continuously participating in global partnership opportunities through programs like Bio Health Worldwide Online that support our global expansion.” She added, “Liquid biopsy has recently risen as one of the most anticipated areas in the healthcare field, and we are now prepared better than ever to enter the global precision oncology market with our proprietary technology and competitive pricing.”
IMBDx challanges Liquid Biopsy with NGS-Based Multi-Markers
IMBDx, a domestic bio start-up company, has undertaken the challenge to enter the global liquid biopsy market in 2020. The domestic bio start-up company is headed by Prof. Kim Tae-You of Seoul National University, Director Kim Hwang-Phill of the research center,